Welcome to our dedicated page for Astria Therapeutics SEC filings (Ticker: ATXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Astria Therapeutics, Inc. (ATXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq‑listed biopharmaceutical issuer. Astria’s filings, including Forms 8‑K, 10‑K, and 10‑Q when available, document key information about its clinical‑stage programs in hereditary angioedema and atopic dermatitis, as well as its material agreements and corporate transactions.
Recent Form 8‑K filings illustrate how Astria uses SEC reports to communicate significant events. One 8‑K describes an Agreement and Plan of Merger with BioCryst Pharmaceuticals, Inc., under which a BioCryst subsidiary will merge with and into Astria, with Astria surviving as a wholly owned subsidiary if closing conditions are met. The filing outlines the cash and stock consideration, treatment of common stock, preferred stock, options, and warrants, and notes that Astria common stock is expected to be delisted from Nasdaq and deregistered under the Exchange Act if the merger is consummated.
Another 8‑K details a license agreement with Kaken Pharmaceutical Co., Ltd., granting Kaken exclusive rights to develop, package, and commercialize navenibart in Japan for prevention of hereditary angioedema attacks, including financial terms such as an upfront payment, potential milestones, and tiered royalties, as well as Kaken’s obligations to support Phase 3 development and handle regulatory submissions in Japan. Additional 8‑K filings cover quarterly financial results and other corporate updates.
On Stock Titan, these SEC filings are paired with AI‑powered summaries that explain the core points of lengthy documents, helping readers quickly understand merger terms, licensing economics, clinical development commitments, and capital considerations. Real‑time updates from EDGAR ensure new Astria filings, including future 10‑K annual reports, 10‑Q quarterly reports, and any Form 4 insider transaction reports, are surfaced promptly, while AI‑generated highlights make dense regulatory language more accessible for investors researching ATXS.
Astria Therapeutics director Jonathan Violin reported automatic changes to his holdings following the company’s merger with BioCryst Pharmaceuticals. On January 23, 2026, Astria became a wholly owned subsidiary of BioCryst through a merger, and each Astria common share was converted into the right to receive 0.59 of a BioCryst common share plus
Astria Therapeutics’ Chief Medical Officer, Christopher Morabito, reported the cash-out of stock options tied to the company’s acquisition by BioCryst Pharmaceuticals. On January 23, 2026, in connection with a merger where Axel Merger Sub, Inc. combined with Astria and Astria became a wholly owned subsidiary of BioCryst, two stock option awards covering 80,000 and 262,500 shares of common stock were disposed of.
According to the merger agreement, each Astria stock option with an exercise price below $13.00 became fully vested and exercisable at the effective time of the merger and was then canceled in exchange for a cash payment equal to the number of underlying shares multiplied by the excess of $13.00 over the option’s exercise price, without interest. Options with exercise prices at or above $13.00 were canceled for no consideration and are not reported on this form.
Astria Therapeutics CEO Jill C. Milne reported the cancellation of her Astria equity holdings in connection with the company’s merger with BioCryst Pharmaceuticals. On January 23, 2026, she disposed of 4,377 shares of common stock, leaving her with no directly held Astria common shares.
On the same date, two blocks of Astria stock options were reported as disposed of: a 195,000-share option with a $6.51 exercise price and a 761,000-share option with a $6.41 exercise price, with zero options remaining after the transactions. Under the merger terms, each Astria share outstanding at the effective time (other than excluded shares) was converted into the right to receive 0.59 BioCryst common shares plus $8.55 in cash per share, subject to taxes. In-the-money Astria options became fully vested and were canceled in exchange for a cash payment based on a $13.00 reference price.